To Get more Insights,  Request A Free Sample 

Market Dynamics

Driver: Rising Incidence of Infectious Diseases

Rising Incidence of infectious diseases such as cholera, typhoid and others are expected to propel the growth of oral vaccines market over the forecast period. Cholera outbreaks vary in frequency across countries, occurring regularly in some and sporadically in others, often years apart. Cholera cases reported to WHO have risen in recent years, with 535,321 cases and 4,007 deaths reported in 2023 across 45 countries. Similarly, as of 2019, typhoid fever affects an estimated 9 million people annually, causing 110,000 deaths. The WHO recommends typhoid conjugate vaccines for children as young as six months and adults up to 45 or 65 years, depending on the vaccine. Since 2017, two WHO-prequalified vaccines have been introduced into childhood immunization programs in typhoid-endemic regions.

Diseases such as cholera, rotavirus, typhoid, and polio remain widespread in many regions, particularly in low- and middle-income countries with limited access to healthcare and sanitation. Oral vaccines are particularly valuable in these areas due to their ease of administration, non-invasive delivery, and suitability for mass immunization campaigns.

For instance, oral cholera vaccines have been critical in managing outbreaks in regions affected by natural disasters, conflict, or displacement, where traditional healthcare infrastructure is compromised. Similarly, the use of oral rotavirus vaccines has significantly reduced hospitalizations and mortality in children under five years old, particularly in countries with high diarrhea-related deaths. The rising awareness of these diseases and the need for preventive measures have led to increased adoption of oral vaccines, driving market growth. Additionally, innovations in oral vaccine technology, such as improved formulations for stability and efficacy, are further expanding their application to new diseases, amplifying their market impact.

Restraint: Tolerance of Oral Vaccines in Harsh Gastrointestinal Environments

A significant challenge restraining the growth of the oral vaccine market is the need for oral vaccines to endure the harsh conditions of the gastrointestinal tract. These include the highly acidic environment of the stomach, varying pH levels throughout the digestive system, and the presence of proteolytic enzymes that can break down proteins and compromise vaccine potency. Unlike injectable vaccines, which benefit from a variety of immune adjuvants to enhance the immune response, oral vaccines face a notable shortage of mucosal adjuvants. To address this issue, researchers are developing novel oral vaccine adjuvants that are safer and capable of maintaining stability and efficacy in these challenging environments.

Trends: Government Support Towards New Product Approvals

Government support plays a crucial role in driving the growth of the oral vaccine market by accelerating the development, approval, and distribution of innovative vaccines. Regulatory agencies and governments across the globe are actively promoting the development of oral vaccines to address unmet needs in infectious disease prevention and pandemic preparedness. For instance, in 2024 Vaxart received a $453 million award from BARDA to fund a Phase 2b study comparing its oral COVID-19 vaccine with an FDA-approved mRNA vaccine. The trial will enroll 10,000 subjects, with an interim efficacy analysis expected in early 2025. The study will focus on both symptomatic and asymptomatic disease, immune response, and safety.

Similarly, the World Health Organization (WHO) has played a pivotal role in expediting the prequalification of oral cholera vaccines, such as Dukoral and Shanchol, to combat cholera outbreaks in regions like sub-Saharan Africa and Southeast Asia. This has improved vaccine access and demonstrated the impact of government and global health organization support in addressing critical health challenges.

Furthermore, Oral vaccines are preferred for large-scale vaccination campaigns due to their ease of administration, prompting governments in low- and middle-income countries to fund immunization programs. For example, India's support for ROTAVAC, a locally produced oral rotavirus vaccine, has significantly reduced child deaths from rotavirus diarrhea. Additionally, initiatives like the Coalition for Epidemic Preparedness Innovations (CEPI), funded by multiple governments, support oral vaccine research for diseases like Lassa fever and Nipah virus. These efforts accelerate R&D, shorten approval timelines, and encourage private-sector investment, driving growth and innovation in the oral vaccine market.

Segmental Analysis

Vaccine Type Insights

In 2024, the live attenuated vaccine segment holds a substantial share of approximately 35% of the total the oral vaccine market, primarily due to its ability to elicit strong and long-lasting immune responses. Live attenuated vaccines, which use weakened forms of pathogens, closely mimic natural infections and typically require only one or two doses to provide lifetime protection against certain diseases. This segment's dominance stems from its effectiveness in preventing diseases such as measles, mumps, rubella (MMR combined), rotavirus, smallpox, chickenpox, and yellow fever. A notable example is the oral polio vaccine (OPV), which has been instrumental in global polio eradication efforts. Additionally, in August 2024, Indian Immunological Limited (IIL) developed a live attenuated, needle-free intranasal booster vaccine for Sars-CoV-2 in collaboration with Griffith University, Australia.

Meanwhile, the inactivated vaccines segment is expected to grow at a significant CAGR during the forecast period. These vaccines contain killed or inactivated pathogens, making them safer and less reactogenic, especially for populations where live vaccines may pose risks. However, inactivated vaccines often require multiple doses to build immunity, as they do not provide the same level of immune response as live vaccines. Currently, six licensed viral inactivated vaccines use formaldehyde or BPL for inactivation. This segment's growth is driven by its higher safety profile, technical feasibility, and suitability for diverse populations.

Application Insights

Based on applications, polio dominates the oral vaccine market due to its long-standing global vaccination efforts and the established use of oral polio vaccines (OPV), which are cost-effective and easy to administer. The disease has been a focal point of global eradication programs, such as the Global Polio Eradication Initiative (GPEI), supported by organizations like the WHO and UNICEF. OPVs are particularly valuable in mass immunization campaigns, especially in low-resource settings, as they do not require medical professionals for administration and are effective at preventing transmission. Continued international funding and commitment to eradicating polio ensure sustained demand for these vaccines, solidifying their dominance in the market. Additionally, the cancer vaccines market is projected to grow at a robust CAGR of approximately 18% during the forecast period. This growth is driven by the rising incidence of cancer globally, fueling demand for preventive and therapeutic vaccines.

Target Population Insights

In 2024, the pediatric segment dominated the oral vaccine market accounting nearly 56% of the market share, driven by the critical need to protect children from thousands of germs they encounter daily and to strengthen their natural defense systems. Vaccination is routinely recommended for infants and children under age 7, with oral polio vaccines (OPV) widely administered across many countries to prevent outbreaks. Additionally, COVID-19 vaccines are authorized for healthy children under 5 years old by the Academy of Pediatrics (AAP), and two oral rotavirus vaccines are licensed for infants.

Meanwhile, the adult segment is projected to grow at the fastest CAGR during the forecast period. This growth stems from the importance of vaccinations in maintaining adult health and fostering a healthier environment for others. Vaccines given in childhood can lose effectiveness over time, necessitating booster doses or new vaccinations as people age. Common oral vaccines for adults include those for rotavirus, adenovirus, cholera, and typhoid, as well as hepatitis B vaccines recommended for individuals over 50.

End Users Insights

In 2024, hospitals & vaccination centers dominated the oral vaccine market holding more than 60% of the market share due to their extensive immunization programs and efficient distribution systems, ensuring timely delivery of vaccines and medical supplies to various healthcare facilities. Meanwhile, clinics are expected to see significant growth, driven by their role in vaccine storage, handling, and administration, particularly for individuals at occupational risk. Clinics also provide post-vaccination care, monitor for adverse reactions, and educate patients, making them integral to expanding vaccination coverage

Distribution Channel Insights

Hospital pharmacies hold the highest share of about 49% of the market share for in and outpatients, driving significant demand. Meanwhile, online pharmacies exhibit the highest CAGR as they leverage the convenience of home delivery, rising digital health adoption, and expanding e-commerce infrastructure. Growing consumer preference for hassle-free access and cost-effective solutions fuels this rapid growth, especially in regions with advanced internet penetration and supportive regulations.

 To Understand More About this Research:  Request A Free Sample 

Regional Insights

Among all the regions, North America led the global oral vaccine market in 2024, driven by its advanced healthcare infrastructure and significant investments in vaccine research and development. Mandatory vaccination laws for schoolchildren, healthcare workers, and residents of healthcare facilities further support market dominance, ensuring widespread immunization. The presence of the FDA ensures the safety, efficacy, and quality of vaccines through stringent regulations and oversight. Notably, the U.S. government allocated $31.9 billion in 2023 for the development and procurement of mRNA vaccines to combat COVID-19 and prepare for future pandemics. Additionally, in 2024, the U.S. is supporting GAVI to enhance immunization access in lower-income countries.

However, Europe is poised to be the fastest-growing oral vaccine market during the forecast period, bolstered by regional collaborations aimed at achieving comprehensive vaccine coverage and fostering awareness. The region emphasizes innovation and value in immunization, recognizing its significant societal returns—adult vaccination programs alone yield up to 19 times the initial investment. 

Key Players in Oral Vaccines Market 

• Sanofi
• GSK
• Takeda Pharmaceuticals
• Soligenix
• Liquidia Technologies
• Elasmogen
• Abivax
• Oravax Medical
• Rapid Dose Therapeutics
• AVRO Life Science
• Prokarium Ltd
• Matinas Biopharma
• ACM Biolabs
• Alcami
• Other Prominent Players

Segments Covered in The Report 

By Vaccine Type 

• Live Attenuated
• Inactive
• Recombinant
• Subunit
• Others

By Application

• Polio
• Tuberculosis
• Rabies
• Influenza
• Cholera
• Cancer
• COVID 19
• Others

By Target Population

• Paediatric Population (Children)
• Adults
• Geriatric Population

By End Users

• Hospitals & Vaccination Centres
• Home Care Settings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography 

• North America
  • The USA
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America